Actinium Pharmaceuticals Updates Status Of Bone-Blood Cancer Treatments

Actinium Pharmaceuticals Thursday said it would host a webinar on its drug Actimab-A for the treatment of acute myeloid leukemia (AML), a type of bone-blood cancer, on July 13. Actinium said, “Until this year, Mylotarg, which targets CD33, was the only drug approved for the treatment of AML in several decades. The drug was withdrawn from the market and the sponsor (Pfizer, PFE) recently resubmitted a BLA (biologics license application) to the FDA (Food and Drug Administration) and an FDA Advisory committee meeting will be held on July 11.”

The company added that it believes that its “actinium-225 radioisotope approach may be most beneficial to patients based on the promising efficacy and safety profile that has been demonstrated in multiple clinical trials to date. In addition, we look forward to providing an update on the Actimab-A phase 2 trial which is on track for interim results later this year in light of these developments.”

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Comment